<DOC>
	<DOC>NCT01019070</DOC>
	<brief_summary>The purpose of this study is to assess the effects of hepatic impairment on the multiple dose pharmacokinetics of BMS-650032.</brief_summary>
	<brief_title>Hepatic Impaired Subjects Compared to Healthy Subjects Receiving Multi-dose BMS-650032</brief_title>
	<detailed_description />
	<mesh_term>Hepatic Insufficiency</mesh_term>
	<criteria>Male and female subjects aged 18 to 70, with hepatic impairment conforming to ChildPugh class A,B or C Each matched control subjects determined to be healthy History of esophageal and gastric bleeding within the past 6 months Primarily cholestatic liver disease Active alcoholic hepatitis Stable encephalopathy of â‰¥Stage 2 Presence of severe ascites or edema Presence of hepatopulmonary or hepatorenal syndrome Positive for HIV Positive for HCV, unless HCV RNA is undetectable</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>